Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GD2IL18CART + Bevacizumab in Relapsed/Refractory GD2+ Solid Cancers
NCT07897968Phase 1Not yet recruiting
- Sponsor
- Universität Münster
- Start
- Oct 2027
- Primary completion
- Sep 2031
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GD2-IL18-CAR-T in neuroblastoma, Ewing sarcoma and osteosarcoma (OS), sponsored by Universität Münster. Primary endpoints: Incidence and severity of adverse events at 12 months, Dose-limiting toxicities at 28 days and 2 more. Planned start Oct 2027; status: not yet recruiting.
02
Drugs
GD2-IL18-CAR-T
03
Conditions
neuroblastomaEwing sarcomaosteosarcoma (OS)
Beyond the preview
Go deeper on NCT07897968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07897968.